Esketamine combined with dexmedetomidine
ApprovedSmall molecule
Esketamine combined with dexmedetomidine is one of 34 small molecule programs targeting Sedation. It is currently in Approved.
3
Indications
3
Total Trials
3
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
167 competitors in Delirium
#DrugCompanyPhaseTrials
1Ritalin
NovartisPhase 3
Victoza
Novo NordiskPhase 3
Luvox
SSolvay Pharmaceuticals
Phase 3
Intuniv
PPromius Pharma, LLC
Phase 3
Neurontin
VViatris Specialty LLC
Phase 3
Esketamine combined with dexmedetomidine
TThe First Affiliated Hospital with Nanjing Medical University
Approved
IV Acetaminophen
AAFT Pharmaceuticals, Ltd.
Phase 3
Rozerem
TakedaPreclinical
Inapsine
Alnylam PharmaceuticalsPreclinical
Anerem
AAcacia Pharma Ltd
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sedation1 trial
Safety and Efficacy of Esketamine Combined With Dexmedetomidine for Sedation of Mechanically Ventilated Patients
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 4·NCT05466708·100 enrolled
Postoperative Sleep Quality1 trial
Dexmedetomidine1 trial
Safety and Efficacy of Esketamine - Dexmedetomidine Combination Versus Dexmedetomidine Monotherapy for Hyperactive Delirium in ICU Patients on Non-Invasive Respiratory Support (SEED-NIRS Trial): Study Protocol of a Randomized Controlled Trial
Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Approved·NCT07377981·388 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details